Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trainor

Showing results (1131-1140 of 1,242) with videos related to

Pageof 125
Sort By:
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonistsCarolyn D Dzierba, Thais M Sielecki, Argyrios G Arvanitis, et al.
Neurology. Genetics|July 13, 2023
Longitudinal Analysis of Respiratory Function of Different Types of Limb Girdle Muscular Dystrophies Reveals Independent TrajectoriesRobert Muni-Lofra, Eduard Juanola-Mayos, Marianela Schiava, et al.
British Journal of Cancer|May 12, 2020
Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasionNick Hornigold, Karen R Dunn, Rachel A Craven, et al.
Journal of Medicinal Chemistry|April 4, 2007
Dihydropyridopyrazinones and dihydropteridinones as corticotropin-releasing factor-1 receptor antagonists: structure-activity relationships and computational modelingCarolyn D Dzierba, Andrew J Tebben, Richard G Wilde, et al.
Journal of Medicinal Chemistry|November 15, 2002
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2)Eddy W Yue, C Anne Higley, Susan V DiMeo, et al.
British Dental Journal|November 12, 2022
Oral prehabilitation for patients with head and neck cancer: getting it right - the Restorative Dentistry-UK consensus on a multidisciplinary approach to oral and dental assessment and planning prior to cancer treatmentLorna K McCaul, Stewart Barclay, Peter Nixon, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 27, 2004
Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in ratsSnjezana Lelas, Harvey Wong, Yu-Wen Li, et al.
JAMA Internal Medicine|November 17, 2015
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health ServicesAlbert Y Liu, Stephanie E Cohen, Eric Vittinghoff, et al.
The New England Journal of Medicine|June 14, 2018
Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic KetoacidosisNathan Kuppermann, Simona Ghetti, Jeff E Schunk, et al.
Clinical Biochemistry|September 28, 2014
Absolute and relative changes (delta) in troponin I for early diagnosis of myocardial infarction: Results of a prospective multicenter trialAlan B Storrow, Richard M Nowak, Deborah B Diercks, et al.
Pageof 125

Showing results (1131-1140 of 1,242) with videos related to

Sort By:
Pageof 125
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonistsCarolyn D Dzierba, Thais M Sielecki, Argyrios G Arvanitis, et al.
Neurology. Genetics|July 13, 2023
Longitudinal Analysis of Respiratory Function of Different Types of Limb Girdle Muscular Dystrophies Reveals Independent TrajectoriesRobert Muni-Lofra, Eduard Juanola-Mayos, Marianela Schiava, et al.
British Journal of Cancer|May 12, 2020
Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasionNick Hornigold, Karen R Dunn, Rachel A Craven, et al.
Journal of Medicinal Chemistry|April 4, 2007
Dihydropyridopyrazinones and dihydropteridinones as corticotropin-releasing factor-1 receptor antagonists: structure-activity relationships and computational modelingCarolyn D Dzierba, Andrew J Tebben, Richard G Wilde, et al.
Journal of Medicinal Chemistry|November 15, 2002
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2)Eddy W Yue, C Anne Higley, Susan V DiMeo, et al.
British Dental Journal|November 12, 2022
Oral prehabilitation for patients with head and neck cancer: getting it right - the Restorative Dentistry-UK consensus on a multidisciplinary approach to oral and dental assessment and planning prior to cancer treatmentLorna K McCaul, Stewart Barclay, Peter Nixon, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 27, 2004
Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in ratsSnjezana Lelas, Harvey Wong, Yu-Wen Li, et al.
JAMA Internal Medicine|November 17, 2015
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health ServicesAlbert Y Liu, Stephanie E Cohen, Eric Vittinghoff, et al.
The New England Journal of Medicine|June 14, 2018
Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic KetoacidosisNathan Kuppermann, Simona Ghetti, Jeff E Schunk, et al.
Clinical Biochemistry|September 28, 2014
Absolute and relative changes (delta) in troponin I for early diagnosis of myocardial infarction: Results of a prospective multicenter trialAlan B Storrow, Richard M Nowak, Deborah B Diercks, et al.
Pageof 125